Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ch14.18/CHO and IL-2 Post-Haploidentical HSCT in Relapsed Neuroblastoma
NCT02258815Phase 2Completed
- Sponsor
- University Children's Hospital Tübingen
- Start
- Aug 2010
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Dinutuximab beta in neuroblastoma, sponsored by University Children's Hospital Tübingen. Primary endpoint: Success of treatment at 180 days. Started Aug 2010; status: completed.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02258815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258815.